Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)
Latest Information Update: 14 May 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Tebentafusp (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Registrational; Therapeutic Use
- Acronyms TEBE-AM
- Sponsors Immunocore
Most Recent Events
- 07 May 2025 According to an Immunocore media release, company is on track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026.
- 10 Jan 2025 According to an Immunocore media release, potential data readouts expected in 2026.
- 02 Dec 2024 Planned number of patients changed from 460 to 540.